Overview

Study of ONO-8577 in Patients With Overactive Bladder

Status:
Completed
Trial end date:
2017-09-26
Target enrollment:
0
Participant gender:
All
Summary
The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Mirabegron
Solifenacin Succinate
Criteria
Inclusion Criteria:

- Patient with symptoms of overactive bladder for ≥6 months

Exclusion Criteria:

- Patient with genuine stress incontinence, or with stress-predominant mixed urinary
incontinence

- Patient who has never experienced urge urinary incontinence during disease duration of
overactive bladder